Analysts expect Danaher Co. (NYSE:DHR) to post $4.92 billion in sales for the current quarter, Zacks reports. Seven analysts have issued estimates for Danaher’s earnings. The highest sales estimate is $4.98 billion and the lowest is $4.77 billion. Danaher reported sales of $4.51 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 9.1%. The firm is expected to issue its next earnings results before the market opens on Thursday, July 19th.
On average, analysts expect that Danaher will report full year sales of $19.91 billion for the current financial year, with estimates ranging from $19.69 billion to $20.03 billion. For the next financial year, analysts forecast that the company will report sales of $20.84 billion per share, with estimates ranging from $20.68 billion to $21.04 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Danaher.
Danaher (NYSE:DHR) last announced its earnings results on Thursday, April 19th. The conglomerate reported $0.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.05. The business had revenue of $4.70 billion during the quarter, compared to analysts’ expectations of $4.54 billion. Danaher had a net margin of 13.56% and a return on equity of 11.39%. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter last year, the company posted $0.85 EPS.
Several research firms have weighed in on DHR. ValuEngine cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Thursday, June 21st. Zacks Investment Research cut shares of Danaher from a “hold” rating to a “sell” rating in a research report on Wednesday, June 20th. Barclays restated a “buy” rating and issued a $113.00 price objective on shares of Danaher in a research report on Friday, April 20th. Morgan Stanley raised their price objective on shares of Danaher from $112.00 to $113.00 and gave the company an “overweight” rating in a research report on Friday, April 20th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $117.00 price objective on shares of Danaher in a research report on Friday, April 20th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $105.69.
In other news, insider Thomas Patrick Joyce, Jr. sold 120,354 shares of the firm’s stock in a transaction dated Friday, April 20th. The shares were sold at an average price of $101.17, for a total value of $12,176,214.18. Following the transaction, the insider now owns 151,959 shares of the company’s stock, valued at approximately $15,373,692.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Daniel L. Comas sold 25,206 shares of the firm’s stock in a transaction dated Friday, April 20th. The shares were sold at an average price of $101.39, for a total transaction of $2,555,636.34. Following the completion of the transaction, the chief financial officer now directly owns 148,769 shares in the company, valued at approximately $15,083,688.91. The disclosure for this sale can be found here. Insiders sold a total of 241,940 shares of company stock worth $24,527,925 in the last ninety days. Insiders own 11.90% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Danaher by 6.2% during the 1st quarter. BlackRock Inc. now owns 43,526,564 shares of the conglomerate’s stock worth $4,261,685,000 after acquiring an additional 2,542,198 shares during the last quarter. Geode Capital Management LLC boosted its stake in Danaher by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 6,263,971 shares of the conglomerate’s stock worth $580,150,000 after acquiring an additional 167,442 shares during the last quarter. Aristotle Capital Management LLC boosted its stake in Danaher by 3.5% during the 1st quarter. Aristotle Capital Management LLC now owns 4,451,816 shares of the conglomerate’s stock worth $435,877,000 after acquiring an additional 150,343 shares during the last quarter. Epoch Investment Partners Inc. boosted its stake in Danaher by 2.1% during the 1st quarter. Epoch Investment Partners Inc. now owns 3,818,204 shares of the conglomerate’s stock worth $373,840,000 after acquiring an additional 77,733 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in Danaher by 5.0% during the 1st quarter. Franklin Resources Inc. now owns 2,851,517 shares of the conglomerate’s stock worth $279,220,000 after acquiring an additional 135,292 shares during the last quarter. 76.61% of the stock is currently owned by institutional investors and hedge funds.
DHR traded up $0.63 during midday trading on Friday, hitting $98.62. The company had a trading volume of 2,013,759 shares, compared to its average volume of 2,412,073. The company has a current ratio of 1.59, a quick ratio of 1.15 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $69.24 billion, a PE ratio of 24.47, a PEG ratio of 1.86 and a beta of 1.03. Danaher has a twelve month low of $78.97 and a twelve month high of $104.82.
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 27th. Stockholders of record on Friday, June 29th will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend is Thursday, June 28th. Danaher’s dividend payout ratio (DPR) is presently 15.88%.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Get a free copy of the Zacks research report on Danaher (DHR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.